IRIS
RICEVUTO, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.373
AS - Asia 4.372
EU - Europa 4.263
SA - Sud America 516
AF - Africa 55
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 6
Totale 16.594
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.289
SG - Singapore 1.904
IE - Irlanda 1.077
CN - Cina 1.053
TR - Turchia 694
SE - Svezia 612
DE - Germania 501
IT - Italia 472
BR - Brasile 445
RU - Federazione Russa 418
HK - Hong Kong 398
UA - Ucraina 337
GB - Regno Unito 320
FI - Finlandia 202
FR - Francia 146
VN - Vietnam 113
IN - India 58
CA - Canada 43
CZ - Repubblica Ceca 42
BD - Bangladesh 34
PL - Polonia 27
AR - Argentina 26
BE - Belgio 24
MX - Messico 23
JP - Giappone 22
IQ - Iraq 18
ZA - Sudafrica 17
NL - Olanda 16
MA - Marocco 14
AT - Austria 12
ES - Italia 11
UZ - Uzbekistan 10
AE - Emirati Arabi Uniti 8
EC - Ecuador 8
KR - Corea 8
AU - Australia 7
CL - Cile 7
CO - Colombia 7
ID - Indonesia 7
LT - Lituania 7
PY - Paraguay 7
SA - Arabia Saudita 7
DM - Dominica 6
EU - Europa 6
KE - Kenya 6
PE - Perù 6
PK - Pakistan 6
PT - Portogallo 6
RO - Romania 6
BG - Bulgaria 5
JO - Giordania 5
VE - Venezuela 5
DZ - Algeria 4
NP - Nepal 4
AZ - Azerbaigian 3
BO - Bolivia 3
CG - Congo 3
DO - Repubblica Dominicana 3
EE - Estonia 3
LU - Lussemburgo 3
RS - Serbia 3
TN - Tunisia 3
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
CR - Costa Rica 2
ET - Etiopia 2
HN - Honduras 2
HR - Croazia 2
IL - Israele 2
JM - Giamaica 2
KG - Kirghizistan 2
LB - Libano 2
MD - Moldavia 2
PA - Panama 2
PS - Palestinian Territory 2
SY - Repubblica araba siriana 2
TL - Timor Orientale 2
BW - Botswana 1
DK - Danimarca 1
GA - Gabon 1
GF - Guiana Francese 1
GH - Ghana 1
HU - Ungheria 1
KH - Cambogia 1
KZ - Kazakistan 1
LV - Lettonia 1
LY - Libia 1
MK - Macedonia 1
ML - Mali 1
MN - Mongolia 1
MY - Malesia 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PG - Papua Nuova Guinea 1
SN - Senegal 1
TH - Thailandia 1
TJ - Tagikistan 1
UY - Uruguay 1
Totale 16.594
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.308
Chandler 1.216
Dublin 1.077
Singapore 1.033
Dallas 814
Boardman 410
Hong Kong 397
Santa Clara 367
Izmir 326
Ashburn 270
Nanjing 236
Wilmington 194
San Mateo 191
Lawrence 168
Princeton 168
Ann Arbor 164
New York 151
Beijing 148
Moscow 99
Milan 86
Nanchang 86
The Dalles 75
Woodbridge 75
Munich 64
Seattle 62
Bremen 61
Los Angeles 60
Shenyang 56
Tianjin 55
São Paulo 53
Helsinki 48
Des Moines 47
Hebei 44
L'aquila 43
Verona 43
Brno 40
Kunming 37
Hefei 35
Columbus 33
Changsha 31
Council Bluffs 29
Jiaxing 29
Hanoi 27
Sant'egidio Alla Vibrata 27
Mountain View 26
Ho Chi Minh City 25
Brussels 24
Warsaw 24
Dong Ket 22
Hangzhou 22
Jinan 22
Shanghai 22
London 21
Norwalk 21
Philadelphia 21
Rome 21
Tokyo 20
Dearborn 19
Guangzhou 19
Zhengzhou 19
Brooklyn 18
Pune 17
San Francisco 17
Auburn Hills 15
Montreal 15
Denver 14
Toronto 14
Falkenstein 13
L’Aquila 13
Phoenix 13
Boston 12
Lanzhou 12
Ningbo 12
Pescara 12
Changchun 11
Falls Church 11
Frankfurt am Main 11
Johannesburg 11
Orem 11
Rio de Janeiro 11
Turku 11
Amsterdam 10
Atlanta 10
Chennai 10
Monza 10
Chicago 9
Curitiba 9
Tashkent 9
Ankara 8
Assago 8
Belo Horizonte 8
Brasília 8
Buffalo 8
Fremont 8
Fuzhou 8
Nuremberg 8
Poplar 8
Stockholm 8
Taizhou 8
Vienna 8
Totale 10.768
Salva come PNG Salva come JPEG
Nome #
Pyrroloquinoline Quinone (PQQ) Attenuates Hydrogen Peroxide-Induced Injury Through the Enhancement of Mitochondrial Function in Human Trabecular Meshwork Cells 343
The supportive care task force at the University of L'Aquila: 2-years experience 178
The prevalent KRAS exon 2 c.35 G > A mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? 174
KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease. 154
Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis. 150
Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer 148
Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines 146
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations. 143
P16 hypermethylation contributes to the characterization of gene inactivation profiles in primary gastric cancer 140
Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study 137
Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro 132
Dose-finding study of oxaliplatin associated to capecitabine based preoperative chemoradiotherapy in locally advanced rectal cancer 132
New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting 128
Antiproliferative and pro-apoptotic effects of 5-azacytidine in prostate carcinoma cells in vitro involve the recovering of PTEN-mediated Akt activity control and androgen sensitivity 127
Oncology together for L'Aquila: early resumption of integrated oncological activities after the earthquake 126
Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, Fir-B/FOx, according to seconde-line treatment and KRAS genotype 125
Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer 124
CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models 123
two simulteneous and very uncommom pi3kca mutations in a liver metastasis from colorectal cancer patient with aggressive and resistant disease 123
Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families 123
Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A 123
Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models 123
Mutazioni della p53 in campioni selezionati di adenocarcinoma del colon dell’Italia Centrale 122
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. 121
A gene expression signature from bone metastases as predictor of clinical outcome in breast cancer patients 120
Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases 119
Pain evaluation and management: a survey of Italian radiotherapists 118
Dose-dense nonpegylated liposomal doxorubicin and docetaxel combination in breast cancer: Dose-finding study 118
Effects of Chemotherapy in Patients with Concomitant Aortic Aneurysm and Malignant Disease 118
Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer 117
Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study 116
p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumors 114
Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). 113
Assessment and treatment of symptoms among italian medical oncologists 111
Symptoms in advanced cancer: The influence of sex, age, Karnofsky Performance Status and PaP score. 111
Hypoxic pelvic perfusion with cisplatin and mitomycin C in multidisciplinary palliative treatment of patients with unresectable recurrent rectal cancer: A retrospective study 111
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis 111
Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells 110
Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line 110
Trifluoroibuprofen inhibits α-Methylacyl Coenzyme A Racemase (AMACR/P504S), Reduces Cancer Cell Proliferation and Inhibits in Vivo Tumor Growth in Aggressive Prostate Cancer Models. 108
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 108
New mutations and protein variants of NBSI are identified in cancer cell lines 107
Multidisciplinary palliation for unresectable recurrent rectal cancer: Hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study 107
Meccanismo d’azione e farmacologia di nuovi composti organometallici nel trattamento del carcinoma del colon-retto. 106
Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients 106
Prognostic relevance of PIK3CA mutations in breast cancer patients treated with primary dose-dense epirubicin/cyclophosphamide -> dose-dense docetaxel 106
Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer. families 105
Oxaliplatin (l-OHP) association with paclitaxel (PTX) or docetaxel (DTX) in NSCLC cell lines: Schedule-dependent activity based on p53/microtubule associated protein 4 (MAP4) interaction 105
Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases 105
Novel P53 mutations detected by FAMA in colorectal cancers 104
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer 104
A KRAS and dual concomitant PI3KCA mutations in a metastatic colorectal cancer patient with aggressive and resistant disease 103
NEW MUTATIONS AND PROTEIC VARIANTS OF NBS1 ARE IDENTIFIED IN CANCER CELL LINES 102
Gabapentin in the treatment of severe sweating experienced by advanced cancer patients 102
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy 102
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 102
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 102
Multidisciplinary management of hepatocellular carcinoma in clinical practice 102
An association of epirubicin, etoposide and cisplatin in gastric cancer: a phase II study 101
Prognostic relevance of KRAS genotype and the prevalent C.35 G > a mutation in metastatic colorectal cancer (MCRC) patients fitting for intensive FIr-B/FOx triplet chemotherapy plus bevacizumab 101
Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy 99
Choice of chemotherapy schedules in elderly patients (> 75 years) with metastatic colorectal cancer (mcrc) according to comorbidity 99
Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs 99
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study 99
Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen 99
Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro 98
Poker association of weekly alternating 5-fluorouracil, irinotecan,bevacizumab and oxaliplatin (FIrB/FOx) in first line treatment of metastatic colorectal cancer: a phase II study 97
ABERRANT HYPERMETHYLATION OF THE P16 GENE IN SPORADIC GASTRIC CANCER 97
Can analysis of the molecular status of the p53 gene contribute to improving the therapeutic strategy for breast carcinoma? 97
Role of immunoscintigraphy in clinical assessment of gastrointestinal tumors 97
Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples. 96
Medical emergencies in oncology: hypercalcemia. II. Diagnosisand therapy 96
Short-term weekly neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer 96
Significato prognostico e predittivo delle alterazioni genetiche nel carcinoma gastrico 95
A six-gene signature predicting breast cancer lung metastasis 95
In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma 94
In vivo bone metastases, osteoclastogenic ability, and phenotypic characterization of human cancer cells 94
Plasma proteomic profiling in hereditary breast cancer reveals a BRCA1-specific signature: Diagnostic and functional implications 94
Familiarity and heredity of tumors in function of an early surgical therapeutic approach 93
Timed-flat infusion of 5-fluorouracil associated with docetaxel as first-line treatment of patients with metastatic breast cancer 92
Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice 92
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. 92
Oxaliplatin:preclinical in vitro studies 92
Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts 92
Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer 91
Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama 90
Intraperitoneal chemotherapy [LA CHEMIOTERAPIA INTRAPERITONEALE] 90
Does the search for large genomic rearrangements impact BRCAPRO carrier prediction? 90
Effectiveness and safety of intensive triplet chemotherapy plus bevecizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer 90
Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation 90
Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models 89
Valutazioni seriate del peptide natriuretico cerebrale sono predittive di cardiotossicità da antracicline in pazienti sottoposti a chemioterapia non ad alte dosi 89
Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-inducedapoptosis in prostate cancer cells 88
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study 88
Role of estrogen receptor alpha in aggressiveness and osteoclastogenic potential of human breast carcinoma cells. 88
Carcinoma della pelvi renale e dell'uretere 88
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. 88
Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient WithKRASMutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy 88
Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy. Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevaizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52 87
Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study 87
Totale 11.085
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.810
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.810
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021882 0 0 0 0 0 70 186 10 178 68 283 87
2021/20221.110 67 88 276 73 32 18 12 55 66 21 76 326
2022/20233.321 233 205 61 358 346 378 5 212 1.375 13 78 57
2023/2024717 116 44 33 103 50 178 16 63 0 28 27 59
2024/20253.197 97 73 308 134 439 268 469 286 678 83 199 163
2025/20263.085 310 635 553 714 553 320 0 0 0 0 0 0
Totale 16.838